HIF1A and melanoma: Moreover, our previous findings have shown that simvastatin (SIM)-a lipophilic statin incorporated in long-circulating liposomes (LCL-SIM) could counteract both causes of cancer resistance to anti-angiogenic treatments as LCL-SIM inhibited B16.F10 murine melanoma growth in vivo via suppression of TAMs-mediated oxidative stress and HIF-1α levels in melanoma cells7.